Cisplatin + Radiation in SCCHN and Correlation With Oxidative Stress Markers

Summary

Patients will receive standard of care radiation therapy to the primary tumor of the head and neck and involved nodal metastasis and draining nodal basin and either weekly cisplatin or every 3-week cisplatin in locally advanced SCCHN. The relationship between cisplatin toxicity and the level of reactive oxygen species generated by the drug in subjects with squamous cell carcinoma of the head and neck treated on this trial.

Timeline

Start

2017-04-11

Primary completion

2024-09-03

Completion

2029-10-31

Drugs

Indications